Browsing Tag
Novartis AG
19 posts
Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings
Novartis reported $14.52 billion in quarterly sales and an 11% increase in core operating profit, but statutory net income declined 70% following a major impairment related to its investigational medicine del-desiran. Strong oncology and immunology sales are helping offset generic competition, while the drug pipeline presents new financial uncertainties.
Why Novartis is paying $575m upfront for an mRNA immune-reset bet worth up to $7.8bn
Novartis has agreed to license Abogen Biosciences’ mRNA-encoded T-cell engager ABO2203 and secure options over additional RNA programs, committing $575 million upfront while leaving most of the headline $7.8 billion value contingent on future development, regulatory and commercial milestones.
Sefaxersen moves toward regulatory talks after Roche delivers positive Phase III IgAN result
Roche’s sefaxersen hits its Phase III IgAN endpoint as the company eyes regulatory talks in a fast-growing kidney disease market.
Novartis Fabhalta wins first FDA traditional approval to slow IgAN kidney decline
Novartis has won FDA traditional approval for Fabhalta to slow kidney function decline in adults with primary IgA nephropathy, upgrading a 2024 accelerated label into the first full complement-inhibitor claim on eGFR. The decision moves Novartis ahead of Vera Therapeutics' Trutakna, which received only accelerated approval on 7 July, and lands one day before the Novartis Q2 2026 earnings release. The commercial question is whether Fabhalta's oral, disease-modifying label can convert into a durable IgAN franchise against a widening field of complement, endothelin and B-cell targeted therapies.
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps. Read how launch execution, pricing and full approval risks shape the next phase.
Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies
Novartis will pay $1.1 billion upfront for preclinical biotech Myricx Bio. Read why its novel ADC payload could reshape oncology strategy and NVS sentiment.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data
Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.